Form 4: Haemonetics Director Lloyd Johnson Receives Restricted Stock Units

Haemonetics Corporation Director Lloyd Emerson Johnson was granted 2,693 restricted stock units as part of the company's long-term incentive plan.

Summary

• Director Lloyd Emerson Johnson of Haemonetics Corp (HAE) was granted 2,693 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on July 24, 2025.
• The RSUs were issued under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
• The RSUs will vest 100% on the first anniversary of the grant date, which is July 24, 2026.
• Following this transaction, Mr. Johnson beneficially owns 12,933 shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The grant of RSUs to a director is a positive signal of alignment between management and shareholder interests, though it is a routine compensation event and not a major catalyst.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and structured approach to equity compensation.

Negatives

• No specific negative aspects are detailed, as this reports a routine equity compensation grant.

Risks

• No specific risks are mentioned.

Future Outlook

The filing indicates a future vesting event for the granted Restricted Stock Units on the first anniversary of the grant date, which is July 24, 2026.

Industry Context

This Form 4 filing reports a routine equity compensation grant to a director, a common practice across various industries to incentivize and retain key personnel by aligning their financial interests with company performance. It does not provide broader industry trends.

Corporate Governance

Related Party Transactions

• Director Lloyd Emerson Johnson, a related party, received 2,693 Restricted Stock Units as part of his compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders by tying compensation to stock performance.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The granted Restricted Stock Units are expected to vest 100% on July 24, 2026, which is the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to a director, which is an expected part of corporate governance and compensation practices. While it aligns the director's interests with shareholders, it is not a significant event that would typically drive a 'buy' or 'sell' recommendation for a seasoned investor. The transaction is part of a pre-planned Rule 10b5-1(c) contract, further indicating its routine nature. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information warranting a change in investment thesis.

Keywords

Haemonetics Corp, HAE, Form 4, Restricted Stock Units, RSUs, Insider Transaction, Director Compensation, Equity Grant, Lloyd Johnson, 10b5-1 plan